Natco Pharma gains on getting nod for Molnupiravir Capsules for Covid-19 treatment in India


Natco Pharma is currently trading at Rs. 899.10, up by 8.65 points or 0.97% from its previous closing of Rs. 890.45 on the BSE.

The scrip opened at Rs. 900.00 and has touched a high and low of Rs. 910.00 and Rs. 895.30 respectively. So far 12163 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 771.00 on 19-Feb-2021.

Last one week high and low of the scrip stood at Rs. 896.85 and Rs. 820.80 respectively. The current market cap of the company is Rs. 16413.78 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 30.31% and 20.82% respectively.

Natco Pharma has received approval for Covid 19 drug Molnupiravir Capsules 200 mg for Indian market, which will be sold under brand name ‘Molnunat’. Molnupiravir is the first Covid drug authorized by Drugs Controller General (India) (DCGI) for the treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death. This capsule was earlier approved in United Kingdom and United States of America.

Molnunat will be marketed by Natco and will be priced affordably. Molnupiravir is the first Covid drug available in Indian market with a minimal dosage duration of 5 days with promising viral clearance. Phase 3 trials of Molnupiravir has shown significant reduction in hospitalization of Covid 19 patients. Molnunat is expected to be launched this week by the company in the Indian market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.



Source link

Leave a Reply